130 related articles for article (PubMed ID: 33993651)
1. Liver fibrosis and all-cause mortality in chronic HCV-infected diabetic patients: A paradoxical association? (ANRS CO22 HEPATHER).
Barré T; Ramier C; Di Beo V; Carrat F; Fontaine H; Marcellin F; Carrieri P; Pol S; Protopopescu C;
Liver Int; 2021 Jul; 41(7):1694-1698. PubMed ID: 33993651
[No Abstract] [Full Text] [Related]
2. Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort).
Santos M; Protopopescu C; Delarocque-Astagneau E; Bourlière M; Petrov-Sanchez V; Di Beo V; Larrey D; Baudoin M; Dorival C; Bureau M; Fontaine H; Carrat F; Marcellin F; Pol S; Carrieri P;
Liver Int; 2022 Jan; 42(1):38-49. PubMed ID: 34520614
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
4. Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort).
Barré T; Nishimwe ML; Protopopescu C; Marcellin F; Carrat F; Dorival C; Delarocque-Astagneau E; Larrey D; Bourlière M; Petrov-Sanchez V; Simony M; Pol S; Fontaine H; Carrieri P;
J Viral Hepat; 2020 Dec; 27(12):1473-1483. PubMed ID: 32810343
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.
Laurain A; Metivier S; Haour G; Larrey D; Dorival C; Hezode C; Zoulim F; Marcellin P; Bourliere M; Zarski JP; Thabut D; Alric L; Ganne-Carrie N; Cales P; Bronowicki JP; Riachi G; Geist C; Causse X; Abergel A; Chazouilleres O; Mathurin P; Guyader D; Samuel D; Tran A; Loustaud-Ratti V; Petrov-Sanchez V; Diallo A; Luzivika-Nzinga C; Fontaine H; Carrat F; Pol S;
BMC Infect Dis; 2019 Apr; 19(1):300. PubMed ID: 30940090
[TBL] [Abstract][Full Text] [Related]
6. Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).
Carrieri P; Bourlière M; Di Beo V; Lusivika-Nzinga C; Ramier C; Antwerpes S; Protopopescu C; Lacombe JM; Pol S; Fontaine H; Mourad A; Carrat F; Duracinsky M; Marcellin F;
Qual Life Res; 2023 Dec; 32(12):3427-3438. PubMed ID: 37587323
[TBL] [Abstract][Full Text] [Related]
7. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F;
J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Impact of Direct-Acting Antiviral Agent Therapy in HCV Cirrhosis: Critical Review.
Fehily SR; Papaluca T; Thompson AJ
Semin Liver Dis; 2019 Jul; 39(3):341-353. PubMed ID: 31041785
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents.
Ciancio A; Ribaldone DG; Dotta A; Giordanino C; Sacco M; Fagoonee S; Pellicano R; Saracco GM
Liver Int; 2021 Feb; 41(2):276-287. PubMed ID: 32998174
[TBL] [Abstract][Full Text] [Related]
10. Signal detection on a patient cohort: A disproportionality analysis of the ANRS CO22 HEPATHER cohort to identify associations between direct acting antivirals and adverse events in patients with hepatitis C virus chronic infection.
Feldman SF; Lapidus N; Dorival C; Diallo A; Amri I; Fontaine H; Pol S; Carrat F;
Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):797-805. PubMed ID: 29749668
[TBL] [Abstract][Full Text] [Related]
11. Antiviral therapy in HCV decompensated cirrhosis: to treat or not to treat?
Navasa M; Forns X
J Hepatol; 2007 Feb; 46(2):185-8. PubMed ID: 17161494
[No Abstract] [Full Text] [Related]
12. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
J Gastroenterol Hepatol; 2017 Mar; 32(3):687-694. PubMed ID: 27577675
[TBL] [Abstract][Full Text] [Related]
13. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
14. Hepatogenous diabetes: Is it a neglected condition in chronic liver disease?
García-Compeán D; González-González JA; Lavalle-González FJ; González-Moreno EI; Villarreal-Pérez JZ; Maldonado-Garza HJ
World J Gastroenterol; 2016 Mar; 22(10):2869-74. PubMed ID: 26973383
[TBL] [Abstract][Full Text] [Related]
15. HCV Therapy in Decompensated Cirrhosis before or after Liver Transplantation: A Paradoxical Quandary.
Bunchorntavakul C; Reddy RK
Am J Gastroenterol; 2018 Apr; 113(4):449-452. PubMed ID: 29206818
[No Abstract] [Full Text] [Related]
16. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517
[TBL] [Abstract][Full Text] [Related]
17. Antiviral treatment for cirrhosis due to hepatitis C: a review.
Somasundaram A; Venkataraman J
Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
[TBL] [Abstract][Full Text] [Related]
18. Letter: can persisting liver stiffness indicate increased risk of HCC, after successful anti-HCV therapy?
Karlas T; Benckert J; Beer S; Keim V; Berg T; Wiegand J
Aliment Pharmacol Ther; 2016 Feb; 43(4):543-4. PubMed ID: 26753820
[No Abstract] [Full Text] [Related]
19. Treatment of chronic hepatitis C virus infection in patients with cirrhosis.
Zeuzem S
J Viral Hepat; 2000 Sep; 7(5):327-34. PubMed ID: 10971820
[TBL] [Abstract][Full Text] [Related]
20. Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin.
Soriano V; Labarga P; Ruiz-Sancho A; Garcia-Samaniego J; Barreiro P
AIDS; 2006 Nov; 20(17):2225-7. PubMed ID: 17086063
[No Abstract] [Full Text] [Related]
[Next] [New Search]
